Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.

Literature DB >> 16129906

Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.

Abstract

Interleukin (IL)-6 is a pleiotropic cytokine with a wide range of biological activities and regulates immunological reactions, inflammatory responses, and hematopoiesis. Overproduction of IL-6 has been shown to be pathologically involved in some inflammatory diseases, such as Castleman's disease, Crohn's disease, and rheumatoid arthritis. Clinical studies have been conducted to investigate a role of IL-6 and the therapeutic potential of anti-IL-6 therapy for these diseases using humanized anti-IL-6 receptor antibody (tocilizumab; currently known as MRA). Overall, tocilizumab was well-tolerated, and improvements of signs and symptoms were observed, confirming the pathological role of IL-6 and suggesting that the blockade of IL-6 could become a new and important treatment option in these refractory diseases.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 16129906 DOI： 10.1385/CRIAI:28:3:221

Source DB: PubMed Journal: Clin Rev Allergy Immunol ISSN： 1080-0549 Impact factor: 8.667

60 in total

1. Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines.

Authors: T Noma; T Mizuta; A Rosén; T Hirano; T Kishimoto; T Honjo
Journal: Immunol Lett Date: 1987-07 Impact factor: 3.685

2. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice.

Authors: M Sasai; Y Saeki; S Ohshima; K Nishioka; T Mima; T Tanaka; Y Katada; K Yoshizaki; M Suemura; T Kishimoto
Journal: Arthritis Rheum Date: 1999-08

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal: Lancet Date: 2002-05-04 Impact factor: 79.321

4. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.

Authors: A Desgeorges; C Gabay; P Silacci; D Novick; P Roux-Lombard; G Grau; J M Dayer; T Vischer; P A Guerne
Journal: J Rheumatol Date: 1997-08 Impact factor: 4.666

5. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors: R Madhok; A Crilly; J Watson; H A Capell
Journal: Ann Rheum Dis Date: 1993-03 Impact factor: 19.103

6. Colonic mucosal interleukin-6 in inflammatory bowel disease.

Authors: K Mitsuyama; E Sasaki; A Toyonaga; H Ikeda; O Tsuruta; A Irie; N Arima; T Oriishi; K Harada; K Fujisaki
Journal: Digestion Date: 1991 Impact factor: 3.216

7. Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1).

Authors: C Miyaura; K Onozaki; Y Akiyama; T Taniyama; T Hirano; T Kishimoto; T Suda
Journal: FEBS Lett Date: 1988-07-04 Impact factor: 4.124

8. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors: T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal: Nature Date: 1986 Nov 6-12 Impact factor: 49.962

9. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model.

Authors: H Matsuno; T Sawai; T Nezuka; M Uzuki; H Tsuji; N Nishimoto; K Yoshizaki
Journal: Arthritis Rheum Date: 1998-11

10. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease.

Authors: F Arai; T Takahashi; K Furukawa; K Matsushima; H Asakura
Journal: Dig Dis Sci Date: 1998-09 Impact factor: 3.199

13 in total

1. Assessment of pathologically diagnosed patients with Castleman's disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease.

Authors: Takaaki Ogoshi; Takashi Kido; Kazuhiro Yatera; Keishi Oda; Toshinori Kawanami; Hiroshi Ishimoto; Noriho Sakamoto; Arisa Sano; Chiharu Yoshii; Shohei Shimajiri; Hiroshi Mukae
Journal: Lung Date: 2013-08-13 Impact factor: 2.584

Review 2. Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors: Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal: Chem Rev Date: 2014-10-02 Impact factor: 60.622

3. Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease.

Authors: Arjun Gupta; Balaji Ayyar; Hamid Zia; Weina Chen; Samar Harris; Harris V Naina
Journal: Indian J Hematol Blood Transfus Date: 2015-09-01 Impact factor: 0.900

Review 4. Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors: Hazem E El-Osta; Razelle Kurzrock
Journal: Oncologist Date: 2011-03-25

Review 5. Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes.

Authors: Sine Haugaard Knudsen; Bente Klarlund Pedersen
Journal: Curr Diab Rep Date: 2015-10 Impact factor: 4.810